KG

Krishna Gupta

Founder of REMUS Capital

Greater Boston

Overview

Work Experience

  • Founder & CEO

    2008 - Current

    We're looking for the rebels. REMUS is a VC firm that leads Pre-Seed, Seed, and Series A rounds in Applied AI and Healthcare companies. We have a concentrated investment approach and focus on Building, not Betting. We admire people who think really big. Those who want to craft legendary, contrarian companies that can be worth $5B or more. We are patient, with youth and experience on our side. I founded the firm out of an MIT dorm in 2008, amidst the Great Recession. I've raised over $200M and we've proved ourselves to be exceptional partners across a decade. We are always there in the trenches with you and have brought many million-dollar customers to our companies. I sit on the boards of Aila, Allurion, Ceres Imaging, Cogito, Cohealo, Humanyze, PetaGene, Placester, Presto, Vyome Biosciences, and ZeroCater - we've been the first institutional investor in each. I've also led our investments into ClassPass, Bombfell, Disruptor Beam, Gyft (acquired: First Data), Crocodoc (acquired: Box), and SchoolMint (acquired: Hero K12). https://remuscap.com/team-member/krishna-k-gupta/

  • Co-founder & ex-CEO

    2017

    Spun out of MIT and a YC alum, Presto Automation (Nasdaq: PRST) creates magical productivity technologies for restaurants, including a leading generative voice AI product solution that helps automate drive-thrus for some of the nation’s largest chains. While I was CEO, the stock 4Xed in price and 10Xed in volume, with Presto becoming part of the Russell 2000 index and being featured on Bloomberg TV, CNBC, the WSJ, and several other media outlets.

  • Chairman

    2016

    Leader in weight loss technology, spun out from Harvard (NYSE: $ALUR). I helped incubate Allurion's digital business leading to its conversational AI platform.

  • Chairman

    2016

    Leader in Vertical AI/analytics + embedded finance for agriculture, spun out from Stanford

  • Chairman

    2018

    Vyome is acting on a clear opportunity to leverage world-class Indian talent + cost arbitrage to tackle large US commercial opportunities in biotech and other related research-driven areas, at a time when US-India relations are on the rise. Its initial assets are targeting unmet immuno-inflammation diseases.

  • Board Member

    2015

    Leader in voice AI for call center applications, spun out from MIT

  • Board Member

    2018

    Leader in compression of genomic data, spun out of Cambridge

  • Co-Founder & Board Member

    2013

    Leader in AI for Organizational Health, spun out of MIT

  • Board Member

    2019

    Leader in Augmented Reality for industry

  • Board Member

    2015

    Leader in equipment sharing for hospitals

Relevant Websites